| Evaluation of 611 in Chinese Children With Moderate to Severe Atopic Dermatitis(AD) (NCT07767253) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2026-09-01 |
| A Study of SSGJ-613 in Gout Participants Initiating Urate-Lowering Treatment (NCT07708181) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2026-08-02 |
| A Phase I Study of SSGJ-716 in Healthy Adults and Participants With Moderate-to-Severe Atopic Dermatitis (NCT07693738) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2026-05-18 |
| The Purpose of This Study is to Evaluate the Efficacy and Safety of 627 in the Treatment of UC (NCT07507513) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2026-03-28 |
| A Study to Evaluate the Efficacy and Safty of 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA) (NCT07349329) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2026-03-09 |
| A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS) (NCT07261644) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2025-11-07 |
| The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE (NCT07185269) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2025-09-24 |
| Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis (NCT07042126) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2025-08-05 |
| Evaluation of 627 in Healthy Adult Subjects (NCT07065136) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2025-07-20 |
| Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (NCT07039669) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2025-07-16 |
| A Study of Two Different Formulations of 611 in Healthy Adult Subjects in China (NCT07042113) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2025-07-01 |
| A Phase IIb Study of 610 in Participants With Severe Eosinophilic Asthma (NCT06680947) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2024-12-20 |
| Evaluation of 626 in Healthy Adult Subjects (NCT06674525) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2024-12-02 |
| A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps (NCT06639295) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2024-11-22 |
| A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients (NCT06522828) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2024-10-10 |
| Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis (NCT06554847) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2024-09-23 |
| A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients (NCT06493760) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2024-09-03 |
| Phase I Clinical Study to Evaluate the Safety and Efficacy of SSGJ-706 Monotherapy for Patients With Advanced Solid Tumors (NCT06533605) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2024-08-01 |
| A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients (NCT06412471) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2024-07-26 |
| Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis (NCT06324812) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2024-07-10 |
| Efficacy and Safety Study of 610 in Patients With Severe Asthma (NCT06323213) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2024-06-24 |
| A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients with Advanced Malignant Tumors (NCT06390774) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2024-05-30 |
| An Phase III Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With PsO (NCT06299982) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2024-05-15 |
| A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients (NCT06361927) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2024-05-15 |
| A Study of SSGJ-613 in Gout Subjects Initiating Urate-Lowering Treatment. (NCT06270225) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2024-03-30 |
| A Study to Evaluate 608 in Patients with Ankylosing Spondylitis (AS) (NCT06242652) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2024-03-19 |
| Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis (NCT06173284) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2024-01-22 |
| Evaluation of 611 in Chinese Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease (NCT06099652) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2023-12-08 |
| A Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout (NCT06169891) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2023-12-01 |
| A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps (NCT05865496) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2023-06-30 |
| A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss (NCT05520177) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2022-12-27 |
| Evaluation of 611 in Chinese Adults With Moderate to Severe Atopic Dermatitis (NCT05544591) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2022-10-26 |
| A Phase II Study of 610 in Participants With Severe Eosinophilic Asthma (NCT05528679) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2022-09-01 |
| A Phase Ib/II Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout (NCT05588908) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2022-06-29 |
| A Phase II Study for 609A in the Treatment of Advanced Undifferentiated Pleomorphic Sarcoma (NCT05193214) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2022-01-25 |
| A Dose Ranging Placebo-controlled Double-blind Study to Evaluate the Safety, Pharmacokinetics and Efficacy of 610 in Participants With Severe Eosinophilic Asthma (NCT05584306) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2021-12-06 |
| A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Potential Anti-tumor Effects of SSGJ-705 in Patients With Advanced or Metastatic HER2-expressing Solid Tumors (NCT05145179) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2021-12-01 |
| Evaluation of 611 in Chinese Adult Patients With Moderate-to-Severe Atopic Dermatitis (NCT05641558) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2021-10-18 |
| Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection (NCT05027373) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2021-08-13 |
| 601 Versus Ranibizumab in Patients With Pathological Myopic Choroidal Neovascularization (pmCNV) (NCT04922151) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2021-06-04 |
| A Phase 2 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis (NCT05604898) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2021-04-01 |
| 601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO) (NCT04667897) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2021-01-28 |
| 601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO) (NCT04667910) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2021-01-27 |
| Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer (NCT04466254) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2020-12-07 |
| Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers (NCT04527718) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2020-09-09 |
| Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A in China (NCT03998345) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2020-07-25 |
| Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-5 Humanized Monoclonal Antibody Injection (NCT04445038) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2020-06-12 |
| Randomized, Double Blinded, Placebo Controlled, Single Dose Escalation Study of 608 in Healthy Subjects (NCT04367441) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2019-11-25 |
| Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A (NCT03950297) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2019-05-01 |
| The Study of Drug 601 in Patients With Diabetic Macular Edema (DME) (NCT04151407) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2019-03-08 |
| The Study of Drug 601 in Patients With Wet Age-related Macular Degeneration (wAMD) (NCT04468997) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2018-11-12 |
| A Study of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Metastatic Colorectal Cancer (NCT03356158) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2017-11-15 |